Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
Comprehensive clinical development programs being initiated for each investigational candidate
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Sirius JV will be owned 51% by Sirius and 49% by Adani
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Subscribe To Our Newsletter & Stay Updated